A Tohoku University team led by Keisuke Goda won a $1 million XPRIZE Healthspan Milestone 2 award for engineered exosomes coated with lanthanide ions that selectively bind senescent cells and deliver growth factors and genetic material to the surrounding tissue. In aged mice, treatment improved frailty scores and physical performance across multiple cohorts without safety signals, and interspecies scaling estimates suggest a potential equivalent of more than 15 additional healthy years in humans. Human trials are now planned through Tohoku University Hospital and the university's Healthspan Research Center.
Key Points
- Lanthanide-modified exosomes bind senescent cells and repair surrounding tissue
- Aged mice showed improved frailty scores and physical performance, no safety signals
- Human trials begin; 15-year projection remains mouse-derived extrapolation
Longevity Analysis
Most senolytic strategies remove the offending cells; this approach leaves them in place and rebuilds the tissue environment they degrade, shifting the target from elimination to repair capacity. Frailty scores and physical performance are functional readouts rather than molecular proxies, which makes the mouse data more interpretable — though the projected human benefit rests on species-scaling assumptions that clinical work has yet to test. If the delivery platform generalizes as the team suggests, the same targeting chemistry could support immune competence, cognitive function and skin and hair renewal, all of which decline along shared pathways of accumulated cellular damage.
Original published by Longevity.Technology, by Kyle Umipig.